EPI-PHARE, epidemiology of health products (French National Agency for Medicines and Health Products Safety, and French National Health Insurance), 93285 Saint-Denis cedex, France; University of Paris-Saclay, UVSQ, University Paris-Sud, Inserm, Anti-infective Evasion and Pharmacoepidemiology, CESP (Center for Research in Epidemiology and Population Health), 78180 Montigny le Bretonneux, France.
EPI-PHARE, epidemiology of health products (French National Agency for Medicines and Health Products Safety, and French National Health Insurance), 93285 Saint-Denis cedex, France.
Therapie. 2023 Sep-Oct;78(5):593-603. doi: 10.1016/j.therap.2023.01.002. Epub 2023 Jan 20.
To limit the spread of the coronavirus disease 2019 (COVID 19), sanitary restrictions have been established since March 2020 in France. These restrictions and the waves of contamination may have had consequences on the use of health products in general, and on the use of contraceptives in particular. We aimed to assess the impact of COVID 19 pandemic from March 16th 2020 to April 30th 2021 in France on reimbursed contraceptives. We analyzed data from the French national health insurance database (SNDS) by extracting all oral contraception (OC), emergency contraception (EC), levonorgestrel-intrauterine system (LNG-IUS), copper-intrauterine device (C-IUD) and contraceptive implant dispensations in 2018, 2019, 2020 and to April 30th 2021. We computed the expected use of contraceptives in 2020 and 2021 without pandemic and its associated sanitary restrictions, by taking the annual trend into account. We assessed the evolution of dispensations by type of contraceptive and by age-groups (≤25 years old, between 25 and 35 and >35 years old) between observed and expected dispensations. After 15 months of pandemic, a decrease of all reimbursed contraceptives dispensations had been estimated, compared with what was expected: -2.0% for OC, -5.0% for EC, -9.5% for LNG-IUS, -8.6% for C-IUD, -16.4% for implant. Women under 25 years old were the most impacted by the decrease. This national study showed that the impact of the COVID 19 crisis was global on all reimbursed contraceptives, with different levels of impact depending on the type of contraceptive, the age-group and the severity of the restriction. OC dispensing decreased marginally compared with expectations. The decrease in long-acting contraceptives dispensing was more pronounced, especially for the implant. These results call for continued monitoring of contraceptive use over the long term and for prioritizing access to sexual health services during crises, especially among the youngest women who were most affected in this study.
为了限制 2019 年冠状病毒病(COVID-19)的传播,自 2020 年 3 月以来,法国已实施了卫生限制措施。这些限制和疫情的传播浪潮可能对一般的卫生产品使用产生影响,特别是对避孕药具的使用产生影响。我们旨在评估 2020 年 3 月 16 日至 2021 年 4 月 30 日 COVID-19 大流行对法国报销避孕药具的影响。我们通过从法国国家健康保险数据库(SNDS)中提取 2018 年、2019 年、2020 年和 2021 年 4 月 30 日所有口服避孕药(OC)、紧急避孕药(EC)、左炔诺孕酮宫内节育系统(LNG-IUS)、铜宫内节育器(C-IUD)和避孕植入剂的处方,分析了数据。我们通过考虑年度趋势,计算了没有大流行和相关卫生限制的情况下 2020 年和 2021 年避孕药具的预期使用情况。我们评估了观察到的和预期的处方之间按避孕类型和年龄组(≤25 岁、25-35 岁和>35 岁)分配的变化。在大流行的 15 个月后,与预期相比,所有报销避孕药具的分配都有所减少:OC 减少 2.0%,EC 减少 5.0%,LNG-IUS 减少 9.5%,C-IUD 减少 8.6%,植入物减少 16.4%。25 岁以下的妇女受下降影响最大。这项全国性研究表明,COVID-19 危机对所有报销避孕药具的影响是全面的,影响程度因避孕类型、年龄组和限制的严重程度而异。OC 的分配与预期相比略有下降。长效避孕药具的分配减少更为明显,特别是植入物。这些结果呼吁长期监测避孕药具的使用情况,并在危机期间优先考虑获得性健康服务,特别是在这项研究中受影响最大的最年轻妇女。